Deals

Cliniqa acquired by Bio-Techne July 9, 2015

Overview

Bio-Techne has completed the acquisition of 100% ownership of Cliniqa Corporation.

Cliniqa specializes in the manufacturing and commercialization of quality controls and calibrators as well as bulk reagents used in the clinical diagnostic market.

Bio-Techne Corporation is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities.

Significance

With over 165 510(k) clearances issued by the U.S. Food and Drug Administration, Cliniqa’s experienced management team brings significant clinical diagnostics and regulatory experience to Bio-Techne.

The acquisition strengthens not only Bio-Techne’s Clinical Controls product portfolio, but also its reach into the in vitro diagnostic (IVD)/Clinical Diagnostics segment.

Crosstree’s Role

Crosstree Capital Partners served as exclusive financial advisor to Cliniqa Corporation.

Sub-Sector

Diagnostics and Tools

Type

Merger and Acquisition